sugemalimab
cstone pharmaceuticals
['lung', 'sugemalimab']
$csphf cstone presents pre-specified overall survival data of sugemalimab for first-line treatment of stage iv non-small cell lung cancer at asco 2022 
News and analysis of biomedical, biopharma, biotech, biosciences, pharmaceutical, and technology equities